An update on the efficacy of Venetoclax for chronic lymphocytic leukemia

References

• Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017 Feb 1;28(2):218–227.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat CLL up front. Blood. 2010 Jan 14;115(2):187–197.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar;10(3):456–459.
   PubMed Web of Science ®Google Scholar
• Roberts AW. Therapeutic development and current uses of BCL-2 inhibition. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):1–9.
   PubMedGoogle Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Juárez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context. 2019;8:212574.
   PubMedGoogle Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar;378(12):1107–1120. DOI:10.1056/NEJMoa1713976
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. DOI:10.1056/NEJMoa1815281
   PubMed Web of Science ®Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095–2103.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021 Nov;35(11):3059–3072.
   PubMed Web of Science ®Google Scholar
• Lovell AR, Jammal N, Bose P. Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. Ther Adv Hematol. 2022;13:20406207221116577.
   Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase ii pivotal trial. J Clin Oncol. 2018 Jul 1;36(19):1973–1980.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (London, England). 2010 Oct;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb;18(2):230–240.
   PubMed Web of Science ®Google Scholar
• Ma S, Seymour JF, Brander DM, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021 Sep 9;138(10):836–846.
   PubMed Web of Science ®Google Scholar
• Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase iii study. J Clin Oncol. 2020 Dec 1;38(34):4042–4054.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–2775. DOI:10.1182/blood-2019-01-896290
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1188–1200.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. Abstract presented at: European Hematology Association Congress 2022. Vienna, Austria; 2022 Jun 9-17.
   Google Scholar
• National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic leukemia (Version 2.2023) 2023 [Jan 29, 2023]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
   Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7(8):1213–1219. DOI:10.1001/jamaoncol.2021.1649
   PubMed Web of Science ®Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evi. 2022;1(7):EVIDoa2200006.
   Google Scholar
• Shanafelt TD, XV W, NE K, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Niemann C, Kater AP, et al. A randomized phase iii study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: fCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup gaia (cll13) trial. Blood. 2021;138(Supplement 1):71–71. DOI:10.1182/blood.2020009676
   PubMedGoogle Scholar
• Tedeschi A, Ferrant E, Flinn IW, et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-3111-304) Trial. Blood. 2021;138(Supplement 1):67–67. DOI:10.1182/blood-2021-144336
   Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020 Nov 1;38(31):3626–3637.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e879–e890.
   PubMed Web of Science ®Google Scholar
• Davids MS, Lampson BL, Tyekucheva S, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1391–1402.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839–850. DOI:10.1182/blood.2021015014
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: elevate-TN four-year follow up. J Clin Oncol. 2021;39(15_suppl):7509–7509. DOI:10.1200/JCO.2021.39.15_suppl.7509
   Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Tam CS, Robak T, Ghia P, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020 Oct 13;106(9):2354–2363.
   PubMed Web of Science ®Google Scholar
• Kater AP, Levin MD, Dubois J, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022 Jun;23(6):818–828.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853–3865. DOI:10.1200/JCO.21.00807
   PubMed Web of Science ®Google Scholar
• Allan JN, Siddiqi T, Kipps TJ, et al. Treatment outcomes after undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): fixed duration treatment (Placebo) versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study. Blood. 2022;140(Supplement 1):224–227. DOI:10.1182/blood-2022-160338
   Google Scholar
• Wierda WG, Kipps TJ, Al-Sawaf O, et al. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma. 2022 Dec;63(12):2765–2784.
   PubMed Web of Science ®Google Scholar
• Kater AP, Kipps TJ, Eichhorst B, et al. Five-year analysis of murano study demonstrates enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Blood. 2020 Nov 05;136:19–21.
   Web of Science ®Google Scholar
• Munir T, Cherrill L-R, Webster N, et al. MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the blood cancer UK TAP clarity study. Blood. 2022;140(Supplement 1):222–223.
   PubMedGoogle Scholar
• Harrup RA, Owen C, D’Rozario J, et al. Efficacy of subsequent novel targeted therapies, including repeated venetoclax-rituximab (VenR), in patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) previously treated with fixed-duration venr in the murano study. Blood. 2020;136(Supplement 1):44–45. DOI:10.1182/blood-2020-137415
   Google Scholar
• Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6(15):4553–4557. DOI:10.1182/bloodadvances.2022007812
   PubMed Web of Science ®Google Scholar
• Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020 Mar;188(6):844–851.
   PubMed Web of Science ®Google Scholar
• Waggoner M, Katsetos J, Thomas E, et al. Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia. J Adv Pract Oncol. 2022 May;13(4):400–415.
   PubMedGoogle Scholar
• Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018 Sep 15;24(18):4371–4379.
   PubMed Web of Science ®Google Scholar
• Mato AR, Sharman JP, Biondo JML, et al. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. Haematologica. 2022 Jan 1;107(1):134–142.
   PubMed Web of Science ®Google Scholar
• Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019 Sep;104(9):e434–e437.
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong JN, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019 Mar;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Tian L, Anderson MA, et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022 Nov 17;140(20):2127–2141.
   PubMed Web of Science ®Google Scholar
• Blombery P, Thompson ER, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020 Mar 5;135(10):773–777.
   PubMed Web of Science ®Google Scholar
• Deng J, Paulus A, Fang DD, et al. Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy. Clin Cancer Res. 2022 Dec 15;28(24):5455–5468.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou K, Nian W, et al. A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL). J Clin Oncol. 2022;40(16_suppl):7543–7543. DOI:10.1200/JCO.2022.40.16_suppl.7543
   Web of Science ®Google Scholar
• Davids MS, Chanan-Khan A, Mudenda B, et al. American Society of Hematology Annual Meeting and Exposition. New Orleans, Louisiana: American Society of Hematology; 2022. Blood 2022.
   Google Scholar
• Tam CS, Verner E, Lasica M, et al. Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. Blood. 2021;138(Supplement 1):1419–1419. DOI:10.1182/blood-2021-148451
   Google Scholar
• Liu X, Lou Y, Wu Y, et al. Discovery of HZ-L105, a next generation of bcl-2 inhibitor, overcomes bcl-2 mutation and exhibits superior antitumor activity. Blood. 2022;140(Supplement 1):7798–7799. DOI:10.1182/blood-2022-166997
   Google Scholar
• Lew TE, Anderson MA, Lin VS, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020;4(1):165–173. DOI:10.1182/bloodadvances.2019000864
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951–3959.
   PubMed Web of Science ®Google Scholar
• Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012 Mar 20;30(9):980–988.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group. J Clin Oncol. 2012 Sep 10;30(26):3209–3216.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Howard D, McParland L, et al. Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up. Blood. 2016;128(22):3226–3226. DOI:10.1182/blood.V128.22.3226.3226
   Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–4060. DOI:10.1200/JCO.21.01181
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood. 2021;138(Supplement 1):639–639. DOI:10.1182/blood-2021-153146
   Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England). 2020 Apr 18;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN. J Clin Oncol. 2022;40(16_suppl):7539–7539. DOI:10.1200/JCO.2022.40.16_suppl.7539
   Web of Science ®Google Scholar